Further references used to develop this protocol:
Cuzick, J., I. Sestak, S. Cawthorn, et al. 2015. "Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial." Lancet Oncol 16(1):67-75
Rebbeck, T. R., T. Friebel, T. Wagner, et al. 2005. "Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group." J Clin Oncol 23(31):7804-7810
Shuster, L. T., B. S. Gostout, B. R. Grossardt, et al. 2008. "Prophylactic oophorectomy in premenopausal women and long-term health." Menopause Int 14(3):111-116
Randall, D., S. Morrell, R. Taylor, et al. 2009. "Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia." Cancer Causes Control 20(5):559-566
Jacobi, C. E., N. J. Nagelkerke, J. H. van Houwelingen, et al. 2006. "Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study." Cancer Epidemiol Biomarkers Prev 15(3):429-436
Teams, F. H. collaborative. 2010. "Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study." Lancet Oncol 11(12):1127-1134
Warner, E., H. Messersmith, P. Causer, et al. 2008. "Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer." Ann Intern Med 148(9):671-679
Vogel, V. G., J. P. Costantino, D. L. Wickerham, et al. 2006. "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial." Jama 295(23):2727-2741
Stratton, J. F., P. Pharoah, S. K. Smith, et al. 1998. "A systematic review and meta-analysis of family history and risk of ovarian cancer." Br J Obstet Gynaecol 105(5):493-499
Goss, P. E., J. N. Ingle, J. E. Ales-Martinez, et al. 2011. "Exemestane for breast-cancer prevention in postmenopausal women." N Engl J Med 364(25):2381-2391
Rosenthal, A. N., L. Fraser, R. Manchanda, et al. 2013. "Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule." J Clin Oncol 31(1):49-57
Sherman, M. E., M. Piedmonte, P. L. Mai, et al. 2014. "Pathologic Findings at Risk-Reducing Salpingo-Oophorectomy: Primary Results From Gynecologic Oncology Group Trial GOG-0199." J Clin Oncol 32(29):3275-3283
Tracey E, Kerr T, Dobrovic A, Currow D et al 2010 "Cancer in New South Wales: Incidence and Mortality Report 2008". Sydney: Cancer Institute NSW, August 2010
Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study. Jacobi CE. Nagelkerke NJ. van Houwelingen JH. de Bock GH. Cancer Epidemiology, Biomarkers & Prevention. 15(3):429-36, 2006 Mar.
Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia. Randall D. Morrell S. Taylor R. Hung WT. Cancer Causes & Control. 20(5):559-66, 2009 Jul.
Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study. FH01 collaborative teams. Lancet Oncology. 11(12):1127-34, 2010 Dec
Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. Kuhl CK. Schrading S. Leutner CC. Morakkabati-Spitz N. Wardelmann E. Fimmers R. Kuhn W. Schild HH. Journal of Clinical Oncology. 23(33):8469-76, 2005 Nov 2
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Vogel VG. Costantino JP. Wickerham DL. Cronin WM. Cecchini RS. Atkins JN. Bevers TB. Fehrenbacher L. Pajon ER. Wade JL 3rd. Robidoux A. Margolese RG. James J. Runowicz CD. Ganz PA. Reis SE. McCaskill-Stevens W. Ford LG. Jordan VC. Wolmark N. National Surgical Adjuvant Breast and Bowel Project. Cancer Prevention Research. 3(6):696-706, 2010 Jun.
Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. Cuzick J. Forbes JF. Sestak I. Cawthorn S. Hamed H. Holli K. Howell A. International Breast Cancer Intervention Study I Investigators. Journal of the National Cancer Institute. 99(4):272-82, 2007 Feb 21.
Exemestane for breast-cancer prevention in postmenopausal women.[Erratum appears in N Engl J Med. 2011 Oct 6;365(14):1361] Goss PE. Ingle JN. Ales-Martinez JE. Cheung AM. Chlebowski RT. Wactawski-Wende J. McTiernan A. Robbins J. Johnson KC. Martin LW. Winquist E. Sarto GE. Garber JE. Fabian CJ. Pujol P. Maunsell E. Farmer P. Gelmon KA. Tu D. Richardson H. NCIC CTG MAP.3 Study Investigators. New England Journal of Medicine. 364(25):2381-91, 2011 Jun 23.
Kuhl, C. K., S. Schrading, C. C. Leutner, et al. 2005. "Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer." J Clin Oncol 23(33):8469-8476.
Berg, W. A., J. D. Blume, J. B. Cormack, et al. 2008. "Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer." JAMA 299(18):2151-2163
Domchek, S. M., T. M. Friebel, C. F. Singer, et al. 2010. "Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality." JAMA 304(9):967-975